Dafna Capital Management LLC Akebia Therapeutics, Inc. Transaction History

Dafna Capital Management LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$2.22 - $3.78 $758,749 - $1.29 Million	-341,779 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$2.39 - $13.08 $1.01 Million - $5.51 Million	-420,887 Reduced 55.19%	341,779 $858,000
Q2 2020 Aug 14, 2020	SELL	$6.67 - $13.58 $606,116 - $1.23 Million	-90,872 Reduced 10.65%	762,666 $10.4 Million
Q1 2020 May 15, 2020	BUY	$4.1 - $10.24 $340,299 - $849,920	83,000 Added 10.77%	853,538 $6.47 Million
Q4 2019 Feb 14, 2020	SELL	$3.16 - $6.73 $181,700 - $386,975	-57,500 Reduced 6.94%	770,538 $4.87 Million
Q3 2019 Nov 14, 2019	SELL	$3.55 - $5.4 $8,875 - $13,500	-2,500 Reduced 0.3%	828,038 $3.25 Million
Q2 2019 Aug 14, 2019	BUY	$4.1 - $8.05 $471,499 - $925,750	115,000 Added 16.07%	830,538 $4.02 Million
Q4 2018 Feb 14, 2019	BUY	$5.39 - $9.15 $484,022 - $821,670	89,800 Added 14.35%	715,538 $3.96 Million
Q3 2018 Nov 14, 2018	BUY	$7.44 - $10.65 $111,600 - $159,750	15,000 Added 2.46%	625,738 $5.53 Million
Q1 2018 May 15, 2018	BUY	$9.53 - $15.68 $4.53 Million - $7.45 Million	475,000 Added 349.94%	610,738 $5.82 Million
Q3 2017 Nov 14, 2017	BUY	$13.06 - $19.67 $1.77 Million - $2.67 Million	135,738	135,738 $2.67 Million

121

54.8M

291K

179K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $329M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Dafna Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Dafna Capital Management LLC with notifications on news.